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Abstract
Maternal behavior in rats is a highly motivated and well-organized social behavior. Given the
known roles of serotonin (5-HT) in emotion, motivation, social behavior, and major depression -
and its known interaction with dopamine - it is likely that serotonin also plays a crucial role in this
behavior. So far, there are surprisingly few studies focusing on 5-HT in maternal behavior, except
for maternal aggression. In the present study, we examined the effects of 5-HT2C receptor agonism
and 5-HT2A receptor antagonism on maternal behavior in postpartum female rats. We
hypothesized that activation of 5-HT2C receptors and blockade of 5-HT2A receptors would
produce a functionally equivalent disruption of maternal behavior because these two receptor
subtypes often exert opposite effects on various brain functions and psychological processes
relevant to rat maternal behavior. On postpartum Days 5, 7, and 9, Sprague-Dawley mother rats
were given a single injection of 0.9% NaCl solution, the 5-HT2C agonist MK212 (0.5, 1.0 or 2.0
mg/kg, ip), or the 5-HT2A antagonist MDL100907 (0.05, 0.5 or 2.0 mg/kg, ip). Maternal behavior
was tested 30 min before and 30 min, 120 min, 240 min after injection. Acute injection of MK212
significantly disrupted pup retrieval, pup licking, pup nursing, and nest building in a dose-
dependent fashion. At the tested doses, MDL100907 had little effect on various components of rat
maternal behavior. Across the 3 days of testing, no apparent sensitization or tolerance associated
with repeated administration of MK212 and MDL100907 was found. We concluded that rat
maternal performance is critically dependent on 5-HT2C receptors, while the role of 5-HT2A
© 2013 Elsevier Inc. All rights reserved.
*Corresponding authors: Weihai Chen, PhD, Faculty of Psychology, Southwest University, Tianshen Road 2, Beibei District,
Chongqing, China, Phone: 86-13594021891, whchen@swu.edu.cn, Ming Li, PhD, Department of Psychology, University of
Nebraska-Lincoln, Lincoln, NE 68588-0308, USA, Phone: 402-472-3144, Fax: 402-472-4637, mli2@unl.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Pharmacol Biochem Behav. Author manuscript; available in PMC 2015 February 01.
Published in final edited form as:
Pharmacol Biochem Behav. 2014 February ; 117: 25–33. doi:10.1016/j.pbb.2013.11.034.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
receptors is still inconclusive. Possible behavioral mechanisms of actions of 5-HT2C receptor in
maternal behavior are discussed.
Keywords
5-hydroxytryptamine 2C receptor; 5-hydroxytryptamine 2A receptor; maternal behavior; MK212;
MDL100907
Introduction
Maternal behavior in rats is often used to model human mothering behaviors and to
investigate the neurobiological mechanisms of mothering (Fleming and Corter, 1988;
Fleming and Li, 2003; Rosenblatt, 1989). The full repertoire of rat maternal behavior
includes pup-licking, pup retrieval, nest-building, and nursing, as well as maternal
aggression (Galef, 1981; Rosenblatt and Lehrman, 1963). Extensive research has delineated
the core neural circuits that mediate the expression of maternal behavior, including the
medial preoptic area (MPOA), ventral bed nucleus of the stria terminalis (vBNST), medial
amygdala and ventromedial hypothalamus (VMH) (Numan, 2007; Numan and Insel, 2003).
Recent work shows that the mesolimbic and mesocortical dopamine (DA) systems also play
a role in maternal behavior, especially in the appetitive aspect of this behavior (e.g. pup
retrieval) (Afonso et al., 2007; Febo et al., 2010; Hansen et al., 1991; Keer and Stern, 1999;
Li, 2002; Li and Fleming, 2003; Numan, 2007; Numan et al., 2005). The current view is that
the mesolimbic and mesocortical DA systems are part of a nonspecific or general
motivational system which serves to increase an organism’s responsiveness to a wide variety
of biologically significant stimuli, including pups.
Serotonin is an important neurotransmitter implicated in many psychological processes
relevant to maternal behavior. Surprisingly, there are few studies focusing on 5-HT in
maternal behavior, except for maternal aggression (De Almeida and Lucion, 1994; Veiga et
al., 2007). Earlier studies using lesion and pharmacological tools suggest that disruption of
5-HT neurotransmission only causes a transient and nonspecific deficit (Barofsky et al.,
1983). Recent evidence from studies on mutant mice suggests that 5-HT may be involved in
the regulation of maternal behavior (Alenina et al., 2009; Lerch-Haner et al., 2008). Because
there are at least 14 known 5-HT receptors in the brain (excluding splice variants and edited
isoforms), the specific 5-HT receptor subtype involved is unclear. Our previous work did
suggest that 5-HT2A and/or 5-HT2C receptors are two likely targets. First, acute
administration of 2,5-dimethoxy-4-iodo-amphetamine (DOI, a selective 5-HT2A/2C agonist)
disrupts maternal performance (Zhao and Li, 2010). Second, atypical antipsychotic drugs
such as clozapine, olanzapine, risperidone, and quetiapine - strong antagonists against 5-
HT2A/2C receptors - also disrupt active components of maternal behavior in a dose-
dependent fashion (Li et al., 2005a; Li et al., 2004). Since both atypical antipsychotics and
DOI are nonselective for 5-HT2A versus 5-HT2C receptors, their relative contributions in
regulating maternal behavior is still unclear.
Accumulating evidence suggests that 5-HT2A and 5-HT2C receptors play opposing roles in
various brain functions and psychological processes relevant to rat maternal behavior. For
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example, activation of 5-HT2C receptors decreases dopamine (DA) release in the nucleus
accumbens and cell firing in the ventral tegmental area, whereas activation of 5-HT2A
receptors enhances these measures (Di Giovanni et al., 2000; Di Matteo et al., 2002).
Conversely, blockade of 5-HT2C receptors increases DA release, whereas blockade of 5-
HT2A receptors decreases it (Ichikawa et al., 2001; Millan et al., 1998). In several motivated
behaviors, 5-HT2A and 5-HT2C receptors also exert opposing effects. For example, Popova
and Amstislavskaya reported that administration of 5-HT2A receptor antagonist ketanserin
diminished male sexual motivation and behavioral responses, whereas administration of the
selective 5-HT2C antagonist RS 102221 increased sexual motivation (Popova and
Amstislavskaya, 2002). Also, impulsive action induced by amphetamine, cocaine and
MK801 is reduced by 5-HT2C receptor agonists and 5-HT2A receptor antagonists (Fletcher
et al., 2011). Opposing effects also exist for 5-HT2A and 5-HT2C receptors in modulating
hyperlocomotion induced by MK801 (Martin et al., 1997), in head-twitch response (Vickers
et al., 2001), and in the differential reinforcement of low-rate 72-s task, a behavioral
screening model for antidepressant agents (Marek et al., 1988; O'Donnell et al., 2005). It
appears that activation of 5-HT2C receptors or inhibition of 5-HT2A receptors may decrease
incentive motivation by decreasing dopamine neurotransmission, which could contribute to
their potential maternal-disruptive effects. Therefore, elucidating the precise behavioral
functions of these receptors in maternal behavior is critically important for enhancing our
understanding of the neurochemistry of maternal behavior.
The primary goal of the present study was to determine the respective roles of 5-HT2A and
5-HT2C receptors in maternal behavior. Specifically, we were interested in whether both 5-
HT2C receptor agonism and 5-HT2A receptor antagonism would produce a similar disruption
of maternal performance in postpartum female rats. We took a pharmacological approach by
using a highly selective 5-HT2A antagonist MDL100907 and a highly selective 5- HT2C
agonist MK212.
Materials and Methods
Subjects and housing
Virgin female Sprague-Dawley rats (60–80 days) weighing 200–250 g were purchased from
Experiment Animal Center, Chongqing Medical University, China. They were initially
housed in pairs in transparent cages (47 cm L × 32 cm W × 21 cm H) with corn-cob granule
for bedding in a colony on a 12-hour light/dark cycle (lights on at 08:00). One week after
arrival, each female rat was placed into the cage of a proven stud male for ten days to ensure
pregnancy. Following the mating procedure, pregnant females were singly housed until
parturition after which they were housed together with their litters for the remainder of the
experiment. The rats had free access to food and water in their home cages. All animal
procedures were approved by the animal care and use committee at Southwest University,
China.
Groups and choices of drug doses
The tested drugs were selected on the basis of our extensive literature research that
suggested these drugs represented the best available drugs to test our hypothesis. MK212 (6-
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Chloro-2-(1-piperazinyl)pyrazine hydrochloride) shows an agonist-preferential action at the
5-HT2C receptor (Sanchez and Arnt, 2000). M100907 (R-(1)-a-(2,3-dimethoxyphenyl)21-[2-
(4-flurophenylethyl)]24-piperidine-methanol) has been reported to have a 100- to 300-fold
greater selectivity for 5-HT2A receptors than for 5-HT2C receptors (Johnson et al., 1996;
Kehne et al., 1996; Palfreyman et al., 1993). Three doses of each drug were chosen based on
our literature review: MK212 (Tocris: 5-HT2C agonist) at 0.5, 1.0 and 2.0 mg/kg (Batman et
al., 2005; Filip et al., 2004), and MDL100907 (National Institutes of Health: 5-HT2A
antagonist) at 0.05, 0.5 and 2.0 mg/kg (Wadenberg et al., 2001). At the chosen dose ranges,
MK212 and MDL100907 are behaviorally effective. For example, MK212 was shown to
reduce acute cocaine-evoked hyperactivity at 2.0 mg/kg, but to increase cocaine-evoked
hyperactivity at 0.3 mg/kg (Filip et al., 2004). Similarly, MDL100907 was found to impair
reversal learning at 0.03 and 0.1 mg/kg (Boulougouris et al., 2008). MMK212 was dissolved
in 0.9% saline. MDL100907 was first dissolved in saline with pH 3.5 before the pH was
adjusted to 6.25 using 0.1 M NaOH and 0.1 M HCl. Finally, it was diluted to desired
concentrations with 0.9% saline. All drugs were administered intraperitoneally (ip) in a
volume of 1.0 ml/kg 30 min prior to the start of behavioral tests. This interval was chosen
primarily based on the previous studies regarding MDL100907 (Ferguson et al., 2010;
Fletcher et al., 2012; Griebel et al. 1997; Sorensen et al. 1993) and MK212 (de Mello Cruz
et al., 2005; Miranda et al., 2001; Van de Kar et al., 1992). 0.9% saline was used as vehicle.
Procedure
The basic procedure was similar to what has been described in Zhao and Li (Zhao and Li,
2009a). Briefly, starting two or three days before the first possible expected parturition date,
the subjects were monitored every day for signs of parturition. The day on which the dam
was found with pups at 10:00 a.m. was designated as Day 1 postpartum, and at 17:00 p.m. as
Day 0 postpartum. Once the dam was found with pups, two shredded paper towels were also
provided as nesting materials. On Day 3 postpartum, each litter was culled to eight pups (4
males and 4 females with the most visible milk bands) and all subjects were changed
(moved) to clean observation cages with their litters. Maternal behavior tests were
conducted on Days 5, 7 and 9 postpartum (PP5, PP7, PP9) at the same time of day (around
9:00 am each day). On each test day, maternal behavior was observed at 4 time points, with
the first one at 0.5 h before the drug injections (i.e., baseline), and the rest being carried out
at 0.5, 2, and 4 h after the injections. This time-frame covered the entire acute effect of the
tested drugs. Each test consisted of two phases. The first phase lasted 10 min which
consisted of continuous observations of maternal behavior under the undisturbed condition.
The second phase was a 10-min pup retrieval test starting immediately after the first
undisturbed test. This phase was initiated by taking the 8 pups away from the mother and
destroying the nest. One minute later, the pups were placed in the corner of the cage
diagonal to the nest site. At the end of the 10-min period, unretrieved pups were returned to
the nest site. Both phases were recorded by video cameras and analyzed manually using a
laptop computer with an event recording program (JWatcher, http://
www.jwatcher.ucla.edu/). The raters were blind to each subject’s drug condition. The
following behaviors were recorded and analyzed: pup retrieval (a rat picking up a pup in her
mouth and carrying it back to the nest site), pup nursing (a rat positioning herself over the
pups with legs splayed to accommodate the pups, including hover, high, and low crouching-
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over postures), pup licking (a female rat placing its tongue on the anogenital area and the
rest of a pup’s body), nest building (a rat picking up nesting material in her mouth and
transporting it back to the nest site or pushing the material with her forepaws toward the nest
site). The first and last pup retrieval latencies were defined as the time elapsed from the first
pup approach to the retrieval of the first and eighth pup into the nest, respectively. 600 s was
assigned to non-responders who did not approach or retrieve the testing pups. The number of
animals in vehicle and MK212-2.0 mg/kg groups was seven, and in other groups was six.
Statistical Analysis
Maternal behavior data from the 1st 10 min undisturbed observation period and 2nd 10 min
pup retrieval test period at each test time point were combined and were presented as mean
± SEM, except for the latency data which were displayed as median ± interquartile range.
Frequency and duration (in second) data on PP5, PP7 and PP9 were analyzed separately
using a factorial repeated measures analysis of variance ANOVA) with group (4 levels) as
the between-subjects factor and test time point (3 levels) as the within-subjects factor (a 4 ×
3 ANOVA). Group differences were further investigated using simple main effect tests (one-
way ANOVA) followed by LSD post hoc tests. Because the latency data were not normally
distributed (e.g. the cut-off time set at 600 s), they were analyzed using nonparametric
Kruskal-Wallis test. Once the overall significant effects were determined, two-group
comparisons between the drug and vehicle treatment were performed using Mann-Whitney
U test. Statistical significance was accepted at p<0.05, two-tailed.
Results
MK212 dose-dependently prolonged pup retrieval latency, while MDL100907 had little
effect
Table 1 illustrates the effects of the 3 doses of MK212 and MDL100907 on the first and last
pup retrieval latency at 30 min before and 30 min after injection on PP5, PP7 and PP9 (the
latency data at other test time points are not shown). No significant group difference was
found at 30 min before injection. At 30 min after MK212 administration, Kruskal-Wallis test
revealed a significant overall drug treatment effect on the first and last pup retrieval latency
on PP5, PP7 and PP9 (all ps < 0.001). Mann-Whitney U test showed that rats treated with
MK212 2.0 mg/kg took significantly longer to retrieve their pups to the nest in comparison
to the vehicle treatment (all ps < 0.004), while rats treated with MK212 1.0 mg/kg and 0.5
mg/kg took longer than the vehicle treatment only at some post-injection test time points
(see Table 1). MDL100907 had no effect on these measures in comparison to the vehicle (all
ps > 0.058) (Table 1).
MK212 dose-dependently reduced number of pups retrieved, while MDL100907 had little
effect
Figure 1 shows the results of MK212 and MDL100907 treatment on pup retrieval at each
test time on PP5, PP7 and PP9 in comparison to the vehicle group. Pup retrieval was
significantly impaired in animals treated with MK212 on PP5 (Figure 1A). Repeated
measures ANOVA revealed a main effect of group [F(3, 22) = 7.305, p = 0.001], a main
effect of test time [F(2, 44)= 7.647, p = 0.001], and a significant group × test time
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interaction [F(6,44) = 4.583, p = 0.001] on PP5. Post hoc LSD tests indicated that MK212
2.0 mg/kg group and 1.0 mg/kg group retrieved fewer pups than the vehicle group (p=0.001
and p=0.006, respectively). To identify the time point(s) at which MK212-treated rats
differed from the vehicle-treated rats, one-way ANOVAs followed by post hoc LSD tests
were used. Results showed that dams injected with MK212 2.0 mg/kg retrieved fewer pups
at 30 min and 120 min after drug injection (p = 0.000 and p = 0.031, respectively). Dams
treated with MK212 1.0 mg/kg retrieved fewer pups at 30 min and 240 min after drug
injection (p = 0.003 and p = 0.029, respectively).
The disruptive effect of MK212 was also found on PP7 (Figure 1B). The main effect of
group [F(3, 22) = 5.218, p = 0.007], test time [F(2, 44) = 9.104, p = 0.001], and drug × test
time interaction [F(6, 44) = 5.218, p = 0.001] were significant. Post hoc tests indicated that
MK212 2.0 mg/kg group retrieved fewer pups than the vehicle group (p = 0.002). One-way
ANOVAs on specific test time points showed that dams injected with 2.0 mg/kg of MK212
retrieved fewer pups at 30 min after drug injection (p = 0.002). On PP9, pup retrieval was
still significantly impaired in dams treated with MK212 (Figure 1C). Once again, the main
effect of drug [F(3, 22)=6.537, p = 0.003], test time [F(2, 44) = 14.951, p = 0.000], and drug
× test time interaction [F(6, 44) = 6.161, p = 0.000] were all significant. Dams injected with
2.0 mg/kg of MK212 retrieved fewer pups at 30 min after drug injection (p = 0.000).
Figure 1 (D, E, F) shows the effects of MDL100907 on pup retrieval on the three test days.
There was no significant effect of group, test time or their interaction on any of the test days
(all ps > 0.225), suggesting that MDL100907 at the tested doses did not affect pup retrieval.
MK212, but not MDL100907 dose-dependently impaired pup nursing
Effects of MK212 and MDL100907 on nursing behavior at each test time on PP5, PP7 and
PP9 are shown in Figure 2. On PP5, nursing duration was significantly shortened in mother
rats treated with MK212 (Figure 2A). Repeated measures ANOVA revealed a main effect of
group [F(3, 22) = 6.292, p = 0.003], a main effect of test time [F(2, 44) = 20.717, p = 0.000],
and a significant group × time interaction [F(6, 44) = 4.031, p = 0.003]. Post hoc tests
indicated that the MK212 2.0 mg/kg group and 1.0 mg/kg group were significantly different
from the vehicle group (p = 0.001 and p = 0.005, respectively). One way ANOVAs followed
by post hoc LSD test revealed that MK212 2.0 mg/kg suppressed nursing at 30 min after
injection on PP5 (p = 0.000), but not at any other test time points. MK212 1.0 mg/kg
significantly inhibited nursing at 30 min and 120 min on PP5 (p = 0.003 and p = 0.008,
respectively). Nursing behavior recovered to the vehicle level at 240 min test time point.
The disruptive effect of MK212 on nursing behavior seems to be still present on PP7 (Figure
2B). However, repeated measures ANOVA only revealed a main effect of test time [F(2, 44)
= 12.724, p = 0.000], but no main effect of group [F(3, 22) = 2.377, p = 0.097] and no
significant group × time interaction [F(6, 44)=1.893, p=0.103]. On PP9 (Figure 2C), the
effects of test time [F(2, 44) = 15.865, p = 0.000] and group × time interaction [F(6, 44) =
2.636, p = 0.029] were significant. One way ANOVAs found that MK212 2.0 mg/kg and 1.0
mg/kg suppressed nursing at the 30 min test time (p = 0.012 and p = 0.001, respectively).
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Figure 2 (D, E, F) shows the effects of MDL100907 on nursing behavior on the 3 test days.
Repeated measures ANOVA did not find a main effect of group, nor group × time
interaction on any of the 3 test days (all ps > 0.051), suggesting that MDL100907 at the
tested doses did not affect pup nursing.
MK212, but not MDL100907 dose-dependently reduced pup licking
Figure 3 shows the effects of MK212 and MDL100907 on pup licking at each test time on
PP5, PP7 and PP9. On PP5, repeated measures ANOVAs revealed a main effect of group
[F(3, 22) = 4.890, p = 0.009], a main effect of test time [F(2, 44) = 11.621, p = 0.001], but
no significant group × time interaction [F(6, 44) = 1.097, p = 0.379] in animals treated with
MK212 (Figure 3A). Post hoc tests indicated that MK212 2.0 mg/kg group was significantly
different from the vehicle group (p = 0.001). Dams injected with MK212 2.0 mg/kg had
significantly lower licking activity at 30 min and 240 min after injection (p = 0.019 and p =
0.014, respectively), but no significant at 120 min after injection (p = 0.084).
On PP7, the disruptive effect of MK212 on pup licking was present, but the magnitude did
not reach the significant level (Figure 3B). Repeated measure ANOVAs revealed no main
effect of group [F (3, 22) = 2.987, p = 0.053], test time [F(2, 44) = 2.670, p = 0.080], and no
significant group × test time interaction [F(6, 44) = 1.115, p = 0.369].
On PP9 (Figure 3C), the disruptive effect of MK212 was still present. Repeated measures
ANOVA revealed a main effect of group [F(3, 22) = 3.771, p = 0.025], but no main effect of
test time [F(2, 44) = 0.922, p = 0.405], nor significant group × test time interaction [F(6, 44)
= 1.234, p = 0.307]. One way ANOVAs followed by post hoc LSD tests showed that dams
injected with MK212 at 2.0 and 1.0 mg/kg had a much lower level of licking activity at 30
min (p=0.034 and p=0.009, respectively).
Figure 3 (D, E, F) shows the effects of MDL100907 on pup licking on the three test days.
There was no significant effect of group, or time and group interaction on any of the test
days (all ps > 0.062), suggesting that MDL100907 at the tested doses did not affect pup
licking.
MK212, but not MDL100907 dose-dependently suppressed nest building
Figure 4 (A, B, C) shows the effects of MK212 and MDL100907 treatment on nest building
at each test time on PP5, PP7 and PP9. In comparison to the vehicle group, nest building
activity was severely impaired by MK212 on PP5. Repeated measures ANOVA revealed a
main effect of group [F(3, 22) = 3.827, p = 0.024], but no main effect of test time [F(2, 44) =
0.179, p = 0.836], no significant group × test time interaction [F(6, 44) = 0.240, p = 0.961].
Post hoc tests indicated that the MK212 2.0 mg/kg and 1.0 mg/kg groups had significant
lower nest building activity than the vehicle group (p = 0.005 and p = 0.018, respectively).
One way ANOVAs followed by post hoc LSD tests showed that dams injected with MK212
2.0 mg/kg showed a suppressed nest building activity at 30 min and 240 min after injection
(p = 0.022 and p = 0.027, respectively). MK212 1.0 mg/kg disrupted nest building at 240
min point (p = 0.022) (Figure 4A).
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The disruptive effect of MK212 on nest building was also found on PP7 (Figure 4B). There
was a main effect of group [F(3, 22) = 3.956, p = 0.021], test time [F(2,44) = 4.250, p =
0.021], but no significant group × test time interaction [F(6, 44) = 1.197, p = 0.326]. Post
hoc tests indicated that all three MK212 groups were significantly different from the vehicle
group (p = 0.006 for MK212 2.0 mg/kg; p = 0.011 for MK212 1.0 mg/kg; p = 0.032 for
MK212 0.5 mg/kg). One way ANOVAs followed by post hoc LSD tests showed that
MK212 at 2.0 mg/kg disrupted nest building activity at 30 min and 120 min after injection
(p = 0.006 and p = 0.026, respectively) and 1.0 mg/kg did so at 240 min (p = 0.036).
On PP9, the main effect of group was significant [F(3, 22) = 3.715, p = 0.027], but the
effects of test time [F(2,44) = 0.389, p = 0.680] and group × test time interaction were not
[F(6, 44) = 0.899, p = 0.504]. Post hoc tests indicated that MK212 2.0mg/kg and 1.0 mg/kg
groups were significantly different from the vehicle group (p=0.010 and p=0.009,
respectively). Dams injected with MK212 at 2.0 and 1.0 mg/kg spent significantly less time
on nest activity at 30 min after injection (p=0.005 and p=0.010, respectively).
Figure 4 (D, E, F) shows the effects of MDL100907 on nest building on the three test days.
There was no significant effect of group, test time or their interaction on any of the test days
(all ps > 0.083), suggesting that MDL100907 at the tested doses did not affect nest building.
Time course of MK212 and MDL100907 effects across the three test days
To examine how the effects of MK212 and MDL100907 on maternal behavior were
changed over the three days of testing and with repeated drug administration, we selected
the 30 min post-injection time point and compared the drug effects across the three test days
(PP5, PP7 and PP9) (Figure 5 and 6). Overall, there did not appear to be any consistent
pattern. No apparent sensitization (i.e. increase in the disruptive effect of MK212) or
tolerance (i.e. decrease in the disruptive effect of MK212) was observed. Statistical analysis
also did not find any significant difference between PP5 and PP9 (all ps > 0.05).
Discussion
The present study demonstrated that the 5-HT2C receptor agonist MK212 had a disruptive
effect on pup retrieval, pup licking, pup nursing, and nest building, four major components
of rat maternal behavior. Rats treated with MK212 had a longer pup retrieval latency,
retrieved fewer pups into the nest, spent less time on licking and nursing pups and on
building the disturbed nest. In contrast, the 5-HT2A receptor antagonist MDL100907 had
little effect on these maternal responses. These findings suggest that 5-HT2C receptors play
an important role in the regulation of maternal behavior, and activation of this receptor
system could lead to a disruption of this behavior. In contrast, the role of 5-HT2A receptors
is still not clear, as MDL100907 at the tested doses did not cause any change in maternal
behavior, a negative finding precluding any firm conclusion on the role of 5-HT2A in
maternal behavior.
The most significant finding of the present study was the determination of the involvement
of 5-HT2C receptor in rat maternal behavior. As mentioned in the Introduction, there is a
general lack of research on the role of serotonin in maternal behavior (De Almeida and
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Lucion, 1994; Veiga et al., 2007). Earlier studies using lesion and pharmacological tools
suggest that disruption of 5-HT neurotransmission only causes a transient and nonspecific
deficit (Barofsky et al., 1983). Recent evidence from studies on mutant mice suggests that 5-
HT may be involved (Alenina et al., 2009; Lerch-Haner et al., 2008). Lerch-Haner et al.
reported that Pet-1−/− mouse dams (Pet-1 also known as Fev, is an ETS transcription factor
restrictedly expressed in 5-HT neurons) showed reduced expression of the serotonergic gene
and 5-HT synthesis (Lerch-Haner et al., 2008). Mouse dams also displayed impaired pup
retrieval, nursing and nest building. Alenina et al. reported that the tryptophan hydroxylase
2-deficient dams failed to retrieve their pups into the nest site and nurse them (Alenina et al.,
2009). Because these genes are critical for proper brain maturation and homeostatic
modulation of neural circuits, lack of these genes throughout the lifetime may disrupt the
development of the neural circuits governing maternal behavior. Thus, it is still not clear
whether the maternal deficits seen in these mutant dams are caused by altered 5-HT
neurotransmission (a primary effect) or by changed brain structures (a secondary effect).
Also, none of the previous studies have examined the specific types of 5-HT receptors in
maternal behavior. Previously, we demonstrated that atypical drugs (e.g. clozapine) disrupt
active components of maternal behavior in a dose-dependent fashion (Li et al., 2005a; Li et
al., 2004). Because these drugs possess potent antagonist actions against 5-HT2A/2C
receptors, in addition to their antagonist action on dopamine D2 receptor, we hypothesized
that blockade of 5-HT2A/2C-mediated neurotransmission contributed to their maternal
disruptive effects, which was validated in our published studies. Specifically, we found that
pretreatment of DOI (1.0 and 2.5 mg/kg), a selective 5-HT2A/2C serotonergic receptor
agonist, dose-dependently reversed the clozapine-induced disruption of maternal behavior
(e.g. pup retrieval). Interestingly, rats treated with DOI itself also showed deficits in
maternal behavior. Because both 5-HT2A/2C receptor antagonist clozapine, and agonist
DOI disrupt maternal behavior, these findings suggest that balanced 5-HT2A and/or 5-HT2C
receptor mediated neurotransmission is critical for the normal expression of maternal
behavior. Too little or too much 5-HT signaling via 5-HT2A/2C receptors could lead to
maternal disruptions.
Despite these findings, we are still not clear about the relative roles of each 5-HT2 subtype
(5-HT2A or 5-HT2C) in the maternal behavior. This is because clozapine has dual action on
both 5-HT2A and 5-HT2C receptors, and DOI is nonselective for 5-HT2A versus 5-HT2C
receptors. The present study was designed to further tease this out by using a highly
selective 5-HT2C receptor agonist MK212 and 5-HT2A antagonist MDL100907. We decided
to first test the effects of 5-HT2C receptor agonism and 5-HT2A receptor antagonism on
maternal behavior because 5-HT2A and 5- HT2C receptors often play opposing roles in
various brain functions and psychological processes. We hypothesized that MK212 and
MDL100907 would produce a functionally equivalent disruption of maternal behavior. Our
result that MK212 disrupted various components of maternal behavior supports our
hypothesis that 5-HT2C receptor is critically involved in the normal expression of maternal
behavior. However, the lack of MDL100907 effect was surprising, both inconsistent with
our hypothesis and the ample evidence suggesting the functional equivalency between 5-
HT2A antagonism and 5-HT2C agonism (see introduction). The lack of any effect with
MDL100907 was also unexpected given that DOI’s behavioral effects (Halberstadt et al.,
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2009; Schreiber et al., 1995; Sipes and Geyer, 1995, 1997; Smith et al., 2003), as well as
those of clozapine’s (Kuroki et al., 2003; Li et al., 2010; Meltzer, 2002) are shown to be
primarily mediated by their antagonist action on 5-HT2A. Since the chosen doses of
MDL100907 are behaviorally active, shown to decrease premature (or ‘impulsive’)
responding on the five-choice serial reaction time task (Fletcher et al., 2007; Winstanley et
al., 2004), impair reversal learning (Boulougouris et al., 2008), reduce reinstatement of
nicotine self-administration (Fletcher et al., 2012), and attenuate cocaine-induced
locomotion (Burton et al., 2013), it is difficult to argue that 5-HT2A receptors were not
altered by MDL100907. Nevertheless, the involvement of 5-HT2A receptors in maternal
behavior needs to be further investigated, either by expanding the MDL100907 dose range,
or by using other selective 5-HT2A receptor antagonists or agonists. Notably, the contrasting
effect of 5-HT2C agonism and 5-HT2A antagonism found in the present study is similar to
that reported by Wolf (Wolf et al., 1999), who showed that in a test of female sexual
behavior, SB206553 (5-HT2C antagonist) was more effective than MDL100907 in reducing
lordosis behavior and in attenuating the ability of DOI to facilitate the behavior. They
concluded that 5-HT2C, rather than 5-HT2A, receptors are primarily responsible for the
effects of 5-HT2 receptor-active drugs on lordosis behavior. These differential effects of 5-
HT2C agonism and 5-HT2A antagonism on maternal behavior is also consistent with that of
earlier investigations in other paradigms. For example, the treatment of MDL100907 alone
did not produce a potent effect on conditioned avoidance response (Wadenberg et al., 1998),
but 5-HT2C agonist WAY-163909 reduced avoidance response (Marquis et al., 2007).
Fletcher showed that the 5-HT2C receptor agonist Ro60-0175 reduced nicotine self-
administration responding in both a FR5 and a progressive ratio schedule, and also reduced
responding for food reinforcement; whereas M100907 did not alter responding for nicotine,
or food, on either schedule (Fletcher et al., 2011).
MK212 may disrupt maternal behavior via several possible mechanisms. First, it may
directly activate the 5-HT2C receptors localized in the brain regions important for maternal
behavior, such as the nucleus accumbens, ventral hypothalamus, ventral tegmental area,
medial prefrontal cortex and ventral bed nucleus of stria terminalis, etc. There is
considerable evidence demonstrating that 5-HT2C receptors are localized in these brain
regions (Bubar et al., 2011; Di Giovanni et al., 2006; Millan et al., 1998; Pompeiano et al.,
1994). Second, MK212 may cause maternal behavior deficits through its indirect action on
the dopaminergic systems, which play an important role in the regulation of maternal
behavior. It is well known that activation of 5-HT2C receptors can decrease dopamine
release in the nucleus accumbens and cell firing in the ventral tegmental area (Di Giovanni
et al., 2000; Di Matteo et al., 2002), and this decrease of dopamine neurotransmission is
capable of causing maternal disruption, as both systemic (e.g., haloperidol, a D2 antagonist)
and central injection of dopamine receptor antagonists such as SCH-23390 (a D1
antagonist), pimozide (a D2 antagonist) and cis-flupenthixol (a mixed D1/D2 antagonist) into
the specific brain regions implicated in maternal behavior (e.g., medial preoptic area,
nucleus accumbens) disrupt various active maternal behaviors (Giordano et al., 1990; Keer
and Stern, 1999; Li et al., 2005b; Miller and Lonstein, 2005; Numan et al., 2005; Zhao and
Li, 2012, 2009b). Given the well-known role of dopamine in incentive motivation (Berridge
and Robinson, 1998), and evidence showing that 5-HT2C receptor agonism tends to decrease
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various motivated behaviors (Grauer et al., 2009; Wadenberg and Hicks, 1999), a 5-HT2C
agonist such as MK212 may achieve its maternal disruption by decreasing maternal
(incentive) motivation. Future research should directly address the neuronal pathways that
mediate the modulatory effects of 5-HT2C receptors on the mesolimbic dopamine system
and its role in maternal behavior.
Taken together, in this study, we demonstrated that MK212 dose-dependently disrupts major
components of maternal behavior. In contrast, MDL100907 did not show any effect.
Therefore, 5-HT2C receptors (not 5-HT2A) may be the predominant 5-HT2 receptor in the
relevant brain areas (the mesolimbic and mesocortical dopamine systems and the
hypothalamic regions, etc.) that are involved in the modulation of maternal behavior in rats.
In other words, serotonin may exert its regulatory effects on rat maternal behavior primarily
through 5-HT2C receptor rather than 5-HT2A receptor. Further work is needed to determine
the involvement of 5-HT2A receptors in maternal behavior.
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Highlights
♦ MK212 (a 5-HT2C agonist) disrupted pup retrieval, pup licking, pup nursing,
and nest building.
♦ MDL100907 (a 5-HT2A antagonist) had little effect on various components
of rat maternal behavior.
♦ Across the 3 days of testing, no apparent sensitization or tolerance was
found.
♦ Serotonin 5-HT2C receptor mediates maternal behavior in rats
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Figure 1.
Effects of MK212 (A, B, C) and MDL100907 (E, F, G) treatment on pup retrieval
throughout the three test days (PP5, PP7 and PP9). Number of pups retrieved at each test
time point is expressed as mean ± SEM. The test lasted 10 min. *p<0.05, compared to
vehicle.
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Figure 2.
Effects of MK212 (A, B, C) and MDL100907 (E, F, G) treatment on pup nursing throughout
the three test days (PP5, PP7 and PP9). Nursing duration at each test time point is expressed
as mean ± SEM. * p < 0.05 versus the vehicle group.
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Figure 3.
Effects of MK212 (A, B, C) and MDL100907 (E, F, G) treatment on pup licking throughout
the three test days (PP5, PP7 and PP9). Licking duration at each test time point is expressed
as mean ± SEM. * p < 0.05 versus the vehicle group.
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Figure 4.
Effects of MK212 (A, B, C) and MDL100907 (E, F, G) treatment on nest building
throughout the three test days (PP5, PP7 and PP9). Time spent on building the nest at each
test time point is expressed as mean ± SEM. * p < 0.05 versus the vehicle group.
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Figure 5.
Time course of effects of MK212 on pup retrieval (A), pup nursing (B), pup licking (C), and
nest building (D) at the 30 min time point after injection on each of the 3 test days.
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Figure 6.
Time course of effects of MDL100907 on pup retrieval (A), pup nursing (B), pup licking
(C), and nest building (D) at the 30 min time point after injection on each of the 3 test days.
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